<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cold urticaria</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cold urticaria</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cold urticaria</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marcus Maurer, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarbjit Saini, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cold urticaria, sometimes also called cold contact urticaria or acquired cold urticaria, is a subtype of physical urticaria  (<a class="graphic graphic_table graphicRef50072" href="/d/graphic/50072.html" rel="external">table 1</a>) [<a href="#rid1">1-3</a>]. The physical urticarias are forms of inducible urticaria in which there is a specific and definite stimulus that triggers the development of signs and symptoms. Cold urticaria is characterized by pruritic wheals (hives) and/or angioedema due to cutaneous mast cell degranulation and their release of proinflammatory mediators after cold exposure of the skin. Triggers include skin contact with cold objects, cold liquids, and cold air. Cold urticaria is reviewed here. Other urticaria disorders, including acute and chronic spontaneous urticaria and other forms of inducible urticaria, including physical urticaria, are discussed separately. (See  <a class="medical medical_review" href="/d/html/8109.html" rel="external">"Physical (inducible) forms of urticaria"</a> and  <a class="medical medical_review" href="/d/html/8101.html" rel="external">"New-onset urticaria"</a> and  <a class="medical medical_review" href="/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education"</a> and  <a class="medical medical_review" href="/d/html/8108.html" rel="external">"Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Cold urticaria most frequently affects young adults [<a href="#rid4">4,5</a>]. Males and females are affected with similar frequency in most studies [<a href="#rid4">4,6-8</a>], although one study reported that females were affected twice as often as males [<a href="#rid5">5</a>]. Up to one-half of patients with cold urticaria are atopic, and one-fourth have other types of inducible urticaria, most commonly symptomatic dermographism and cholinergic urticaria [<a href="#rid6">6,8,9</a>].</p><p>The incidence of cold urticaria was estimated to be 0.05 percent in Central Europe [<a href="#rid6">6</a>]. The frequency of cold urticaria among physical urticaria subtypes varies between 5 and 34 percent, partly depending on the geographic region (ie, higher incidences are found in regions with colder climates, and lower rates are seen in regions with a warmer climate) [<a href="#rid4">4,6,10,11</a>].</p><p class="headingAnchor" id="H1778211"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>Cold urticaria is a self-limited disorder in most patients. Remission, or at least improvement of symptoms, occurs in 50 percent of patients within five to six years [<a href="#rid3">3-6,12</a>]. The mean time to resolution in one study was 5.6±3.5 years [<a href="#rid4">4</a>]. Recurrence of cold urticaria after remission is rare. However, some patients have the disorder for many years, and there are lifelong forms of atypical cold urticaria (ie, familial atypical cold urticaria and familial delayed cold urticaria). (See <a class="local">'Atypical forms of cold urticaria'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The underlying pathophysiology of cold urticaria is largely unknown but is likely to involve immunoglobulin E (IgE) mediated mast cell activation in a subgroup of patients [<a href="#rid13">13,14</a>]. Signs and symptoms result from degranulation of mast cells and the resulting release of histamine and other proinflammatory mediators. This results in pruritus, burning, and erythema from activation of cutaneous nerves and vasodilation of skin vessels with extravasation causing wheals and angioedema. Following a cold stimulation test (CST), cutaneous mast cells show signs of degranulation, and skin and serum levels of mast cell mediators are increased [<a href="#rid15">15-18</a>]. On skin biopsy, cold urticaria lacks a late-phase cellular infiltrate, similar to most other forms of physical urticaria (except delayed pressure urticaria) [<a href="#rid19">19</a>].</p><p>A variety of laboratory abnormalities have been found in patients with cold urticaria, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a small series, the majority of patients with cold urticaria exhibited mast cell-activating anti-IgE antibodies [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Associations noted in case reports include cryoglobulinemia, cold agglutinins, anti-lamin-B antibodies, reduced levels of C1 esterase inhibitor and C4, and increased levels of platelet-activating factor (PAF) and platelet factor 4 [<a href="#rid21">21-25</a>].</p><p></p><p class="headingAnchor" id="H4450715"><span class="h2">Associated disorders</span><span class="headingEndMark"> — </span>A number of diseases have been anecdotally associated with cold urticaria, largely in case reports. The causal relationship between these various disorders and cold urticaria is unknown.</p><p class="bulletIndent1"><span class="glyph">●</span>Associations have been reported with various infections, including viral, parasitic, and bacterial infections. Specific disorders include Lyme disease, hepatitis, infectious mononucleosis, acute toxoplasmosis, <em>Helicobacter pylori</em> colonization, and human immunodeficiency virus (HIV) infection [<a href="#rid26">26-30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cold urticaria has been associated with antecedent Hymenoptera stings [<a href="#rid31">31-34</a>], food and drug intolerance [<a href="#rid35">35</a>], and hematologic, lymphatic, or neoplastic conditions [<a href="#rid31">31,36</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical manifestations of all forms of cold urticaria consist of cutaneous wheals and/or angioedema, which form after cold exposure of the skin. A subset of patients develops systemic reactions.</p><p class="headingAnchor" id="H23479940"><span class="h2">Cutaneous signs and symptoms</span><span class="headingEndMark"> — </span>Cold urticaria is characterized by the development of wheal-and-flare skin reactions and/or angioedema after the skin is exposed to cold air, liquids, or objects  (<a class="graphic graphic_picture graphicRef50151" href="/d/graphic/50151.html" rel="external">picture 1</a>) [<a href="#rid12">12</a>]. Wheals and angioedema typically develop minutes after cold exposure and are usually limited to cold-exposed skin areas. Exposure to cold weather is one of the most common triggers for symptoms, with variables that include temperature, humidity, and wind chill factor.</p><p class="headingAnchor" id="H23479947"><span class="h2">Systemic reactions</span><span class="headingEndMark"> — </span>Extensive cold contact, such as swimming in cold water, may result in systemic reactions, with symptoms ranging from generalized wheals to anaphylaxis [<a href="#rid7">7</a>]. Aquatic activities in cold water pose a risk of death, both directly from anaphylaxis and indirectly from drowning during a reaction [<a href="#rid5">5,7,37</a>]. Available studies, mostly of referral populations, suggest that anaphylaxis develops in up to approximately one-third of patients [<a href="#rid4">4,9,38,39</a>]. Patients with cold urticaria are also at risk of suffocation due to oropharyngeal angioedema after consuming cold foods or beverages, although it is unclear how commonly this occurs. Exposure to cold air can also be a trigger for systemic reactions, and we advise patients to pay attention to the wind chill factor during cold months.</p><p class="headingAnchor" id="H4451196"><span class="h3">Risk factors</span><span class="headingEndMark"> — </span>Some risk factors or predictors of systemic reactions have been identified, although this area requires further study [<a href="#rid40">40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The Comprehensive Evaluation of Cold Urticaria and Other Cold-Induced Reactions (COLD-CE) study identified five independent risk factors for cold-induced anaphylaxis: a previous systemic reaction to a Hymenoptera sting, angioedema, oropharyngeal/laryngeal symptoms, concomitant asthma, and itchy earlobes [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other, smaller studies in children and adults identified a previous cold-induced systemic reaction and age of onset &lt;30 years old as other possible risk factors [<a href="#rid4">4,9,37</a>].</p><p></p><p>Physical variables associated with systemic reactions include a greater surface area of skin exposed, exposure to lower temperatures, and longer duration of cold exposure. Exposure to cold water or solid objects that are cold is more likely to elicit symptoms than exposure to cold air.</p><p class="headingAnchor" id="H3768741"><span class="h2">Atypical forms of cold urticaria</span><span class="headingEndMark"> — </span>Up to one-third of cold urticaria patients have atypical cold urticaria, of which there are several forms [<a href="#rid39">39-41</a>]. The signs and symptoms of typical and atypical cold urticaria are similar. However, patients with atypical cold urticaria have negative or atypical results in standardized cold stimulation tests (CSTs). In most patients with atypical cold urticaria, modified cold provocation testing is needed to confirm the diagnosis. (See <a class="local">'Cold stimulation test'</a> below.)</p><p>Some forms of atypical cold urticaria are acquired, and others are hereditary [<a href="#rid17">17,42</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed cold urticaria</strong> – There are both acquired and hereditary forms of delayed cold urticaria, all of which are rare. In these disorders, the wheal-and-flare reaction occurs up to 24 hours after cold exposure [<a href="#rid43">43,44</a>]. Patients have no immediate response to CST but will develop a wheal-and-flare response at the test site, usually 18 to 24 hours later. In the familial form, hyperpigmentation typically develops at the site of lesions following resolution.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial atypical cold urticaria</strong> – In this disorder, symptoms begin in early childhood and are lifelong [<a href="#rid45">45</a>]. Localized whealing typically develops on areas exposed to cold air, water, or objects. Symptoms triggered by cold food and beverages are also common. Systemic inflammatory symptoms are absent. CSTs were negative in the small number of patients described.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cold-dependent dermographism</strong> – In this variant, the skin becomes dermographic when cooled [<a href="#rid46">46,47</a>]. To reproduce this, the skin should be stroked firmly while cool and then rewarmed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cold-induced cholinergic urticaria</strong> – Patients with this variant develop hives only when exercising in cold environments [<a href="#rid48">48</a>]. The diagnosis is often made by clinical history alone and would be confirmed by exercise challenge in a cold room.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic cold urticaria</strong> – In this form of cold urticaria, generalized urticaria is seen after systemic cold exposure. This form is not associated with exercise [<a href="#rid49">49</a>]. CST is negative, and the diagnosis is usually based on clinical history and confirmed by cold exposure in a cold room.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localized cold urticaria</strong> – Patients with localized cold urticaria develop hives following cold exposure but only at defined skin sites, such as the face [<a href="#rid50">50,51</a>]. Thus, the CST is positive only if performed at these sites.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Food-dependent cold urticaria</strong> – Hives develop at the site of the ice cube challenge, but only after the intake of food [<a href="#rid52">52</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>In a patient with a suggestive clinical history, evaluation consists of a cold stimulation test (CST) [<a href="#rid17">17,53,54</a>]. Modified types of testing are often needed for atypical forms. Laboratory testing is not needed in routine cases of cold urticaria in children or adults, although it is appropriate if the patient's symptoms are not typical for cold urticaria or suggest the presence of systemic disease or an associated condition. (See <a class="local">'Associated disorders'</a> above and <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H23480286"><span class="h2">Cold stimulation test</span><span class="headingEndMark"> — </span>A CST can be performed by several different methods. All methods involve the application of a cold object to the skin and then removing the stimulus and allowing the skin to rewarm. The test is considered positive if the test site shows a palpable and clearly visible wheal-and-flare skin reaction upon rewarming. The affected site is pruritic and/or associated with a burning sensation in most cases. The test is considered negative if there is no reaction or erythema or pruritus/burning only.</p><p class="headingAnchor" id="H23480071"><span class="h3">Ice cube test</span><span class="headingEndMark"> — </span>The ice cube test, which requires no special equipment, involves placing an ice cube and a small amount of water in a thin plastic bag, allowing a few minutes for the ice and water temperatures to equilibrate, and then placing the bag against the skin (usually of the volar forearm) for five minutes [<a href="#rid37">37</a>]. The bag is then removed, and response is assessed 10 minutes after removal  (<a class="graphic graphic_picture graphicRef95909" href="/d/graphic/95909.html" rel="external">picture 2</a>). This method is readily performed in most offices and has a sensitivity of 83 to 90 percent and a specificity of 100 percent [<a href="#rid5">5,53</a>]. Longer periods of exposure are rarely needed.</p><p>If no wheal has developed, we revisit the history. Sometimes, an atypical form of cold urticaria is present. As an example, we might ask the patient again if there are only certain areas of the body on which cold-induced wheals and/or angioedema have formed in the past (suggesting localized cold urticaria). Modified testing can sometimes elicit a positive test. (See <a class="local">'Atypical forms of cold urticaria'</a> above.)</p><p class="headingAnchor" id="H1817261147"><span class="h3">Testing methods that are not recommended</span><span class="headingEndMark"> — </span>Cold provocation testing using cold packs or cold water baths is <strong>not</strong> recommended for first-line screening, because these methods expose larger areas of skin to cold and may induce systemic reactions [<a href="#rid7">7,17</a>]. However, cold provocation may be used to evaluate patients in whom the ice cube (or TempTest, if available) method was negative. (See <a class="local">'Specialized testing devices'</a> below.)</p><p class="headingAnchor" id="H1817261153"><span class="h3">Natural exposure testing</span><span class="headingEndMark"> — </span>In some situations, the most logical way to diagnose a cold-induced disorder is to ask the patient to reexpose themself to the conditions (eg, cold wind, cold water) that elicited the signs and symptoms in the first place, if safe and feasible.</p><p class="headingAnchor" id="H4448940"><span class="h3">Specialized testing devices</span><span class="headingEndMark"> — </span>TempTest 4.0 is a thermoelectric device that was developed, validated, and licensed as a commercially available medical product. TempTest 4.0 allows for CSTs, including threshold measurements, with a continuous gradient of temperatures ranging from 4 to 44°C (39 to 111°F)  (<a class="graphic graphic_picture graphicRef95911" href="/d/graphic/95911.html" rel="external">picture 3</a>). (See <a class="local">'Threshold testing'</a> below.)</p><p class="headingAnchor" id="H23480278"><span class="h2">Threshold testing</span><span class="headingEndMark"> — </span>The author's approach in patients who show a positive initial test reaction is to further define a temperature threshold for the individual patient using the TempTest 4.0 device. The critical temperature threshold is the highest temperature sufficient to induce a positive test reaction  (<a class="graphic graphic_picture graphicRef95910" href="/d/graphic/95910.html" rel="external">picture 4</a>) [<a href="#rid42">42</a>]. Threshold testing is not necessary for the diagnosis, although the information can help patients avoid risky situations by knowing what temperatures are likely to elicit symptoms. It can also be used to monitor treatment responses without repeatedly exposing the patient to situations that induce symptoms [<a href="#rid55">55,56</a>].</p><p>A study of 45 patients with cold urticaria found a mean (+ standard error of the mean) critical temperature threshold of 17 (+6°C) or approximately 63 (+11°F) (range 4 to 27°C or approximately 39 to 81°F) [<a href="#rid57">57</a>]. Thus, patients' thresholds may vary significantly. Patients with higher threshold temperatures are considered to have more severe disease, although disease severity does not appear to predict response to antihistamine therapy. (See <a class="local">'Dose'</a> below.)</p><p>One important caveat about threshold determinations is the following. There are no data indicating that threshold levels are the same whether the area of exposure is localized, such as exposure of the face to a cold wind, versus a large area, such as submersion in cold water. We advise patients that if they are faced with a situation in which symptoms might occur (such as swimming in a pool), they can expose a limited area of the body first (eg, submerge a hand) and then wait to see if symptoms appear before exposing the rest of the body.</p><p class="headingAnchor" id="H263705372"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of cold urticaria should be suspected in a patient who develops urticaria and/or angioedema after the skin is exposed to cold air, liquids, or objects  (<a class="graphic graphic_picture graphicRef50151" href="/d/graphic/50151.html" rel="external">picture 1</a>) [<a href="#rid12">12</a>]. Symptoms usually develop some minutes after cold exposure and are usually limited to cold-exposed skin areas. The diagnosis is confirmed by the presence of a positive cold stimulation test (CST). If the CST is negative, the history should be revisited, and an atypical form of cold urticaria should be considered. (See <a class="local">'Cold stimulation test'</a> above and <a class="local">'Atypical forms of cold urticaria'</a> above.)</p><p class="headingAnchor" id="H7"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Disorders other than typical and atypical cold urticaria, in which symptoms are induced by cold exposure, include familial cold autoinflammatory syndrome (FCAS), disorders caused by cold-induced abnormal serum proteins, and cold-induced urticarial vasculitis (rare) [<a href="#rid58">58</a>]. Cold stimulation tests (CSTs) would be negative if performed in patients with these disorders.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial cold autoinflammatory syndrome (FCAS)</strong> – Patients with FCAS present within the first few months of life. The development of a papular rash after cold exposure is often delayed by up to several hours. This form is associated with systemic inflammatory symptoms, including fever, conjunctival injection, and arthralgias. The presence of systemic symptoms distinguishes this disorder from simple cold urticaria. FCAS is considered a hereditary periodic fever syndrome. (See  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders", section on 'Familial cold autoinflammatory syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PLC-gamma-2-associated antibody deficiency and immune dysregulation (PLAID)</strong> – A syndrome of familial cold urticaria related to deletions in the gene for phospholipase C (PLC) gamma-2 was described in 2012 [<a href="#rid59">59</a>]. Affected individuals have cold urticaria from childhood, although symptoms are elicited by evaporative cooling (eg, exposure to cold air or wind) rather than touching cold objects or water, and autoimmunity and immunodeficiency are each present in approximately one-half of patients. Investigators suggested that the condition be called "PLC-gamma-2-associated antibody deficiency and immune dysregulation" (PLAID). (See  <a class="medical medical_review" href="/d/html/122509.html" rel="external">"Autoinflammatory diseases mediated by miscellaneous mechanisms", section on 'PLAID/APLAID'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FXII-associated cold autoinflammatory syndrome (FACAS)</strong> – A four-generation family with cold-induced urticarial rash, arthralgia, chills, headache and malaise associated with an autosomal dominant inheritance was reported in 2020 [<a href="#rid60">60,61</a>]. Genetic studies identified a disease-driving variant in gene F12, which encodes coagulation factor XII, and patients presented with reduced plasma prekallikrein, cleaved high-molecular-weight kininogen, and elevated plasma bradykinin. Treatment with the bradykinin B2 receptor antagonist <a class="drug drug_general" data-topicid="16808" href="/d/drug information/16808.html" rel="external">icatibant</a> or the interleukin (IL) 1 antagonist <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> reduced disease activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disorders of cold-induced protein abnormalities</strong> – Several other diseases involve abnormal cold-dependent immunoglobulins, including cryoglobulinemia, cryofibrinogenemia, cold agglutinin disease, and paroxysmal cold hemoglobinuria. Patients with these disorders do not present with cold urticaria but rather with signs and symptoms of cutaneous (ie, purpura) or systemic vasculitis, kidney disease, or other organ system manifestations. (See  <a class="medical medical_review" href="/d/html/1825.html" rel="external">"Overview of cryoglobulins and cryoglobulinemia"</a> and  <a class="medical medical_review" href="/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria"</a>.)</p><p></p><p class="headingAnchor" id="H10165653"><span class="h1">REFERRAL</span><span class="headingEndMark"> — </span>Straightforward cases of cold urticaria may be diagnosed and managed by generalists. We suggest referral to an allergy/immunology expert if the clinician is not comfortable performing diagnostic testing and in cases involving systemic symptoms or atypical symptoms or if symptoms prove difficult to manage. Patients with cold-induced symptoms that are suggestive of an autoinflammatory or vasculitis disorder should be referred to a rheumatologist.</p><p class="headingAnchor" id="H8"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H279693636"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The management of cold urticaria consists of the following elements:</p><p class="bulletIndent1"><span class="glyph">●</span>Education about the risks of systemic reactions and practical advice to avoid cold exposure</p><p class="bulletIndent1"><span class="glyph">●</span>Preparation for treatment of acute symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of disease activity and control</p><p class="bulletIndent1"><span class="glyph">●</span>Prophylactic treatment</p><p></p><p>The goal of treatment is to achieve disease control and to restore a quality of life that is acceptable to that patient. For example, patients who are content to avoid swimming and other high-risk activities may require minimal pharmacotherapy, while those who are committed to these activities or have occupations that routinely expose them to cold may require more extensive therapy. Patients with cold urticaria who are incompletely treated not only experience avoidable impairment in their quality of life but may also be at greater risk of developing life-threatening reactions upon cold exposure if they have a history of systemic reactions. However, the extent to which antihistamines prevent cold-induced systemic reactions is difficult to predict. Therefore, patients must also be prepared to treat these reactions with <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>.</p><p>Successful desensitization protocols have been described, but this approach requires daily cold exposure to maintain the desensitized state and is impractical for most patients. (See <a class="local">'Cold desensitization'</a> below.)</p><p class="headingAnchor" id="H4449202"><span class="h2">Education about high-risk activities and cold avoidance</span><span class="headingEndMark"> — </span>As soon as the diagnosis has been made, the clinician should begin to educate the patient about the activities and procedures that may trigger systemic reactions or serious localized reactions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Swimming</strong> <strong>–</strong> Swimming is the activity that most commonly induces systemic symptoms [<a href="#rid4">4,9</a>]. Patients who chose to continue to participate in aquatic activities should expose a limited area of the body first (eg, submerge a hand) and then wait to see if symptoms appear before exposing the rest of the body. If a threshold temperature is known for that patient, then they can more easily avoid lower temperatures. A water temperature above 25°C (77°F) is safe for most patients [<a href="#rid9">9</a>]. Wetsuits may be helpful, although this has not been formally studied.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cold foods and beverages</strong> <strong>–</strong> Consumption of cold foods or beverages can induce oropharyngeal angioedema or anaphylaxis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery</strong> <strong>–</strong> Surgery is another setting in which patients with cold urticaria can develop systemic reactions [<a href="#rid62">62,63</a>]. The surgery and anesthesia teams should be informed about the patient's condition and should make efforts to keep the patient sufficiently warm throughout the procedure. Treatment for any symptoms that may develop should be immediately available. Premedication with antihistamines could be considered in patients with past systemic reactions to cold exposure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous fluids and injections</strong> <strong>–</strong> Administration of cold intravenous solutions or injections can induce symptoms in some patients. Symptoms can develop with vaccines, biologics, and other injections given intramuscularly or subcutaneously, depending on the temperature and volume. Intravenous fluids pose the greatest risk and should be prewarmed.</p><p></p><p>General cold avoidance is recommended since it is the most logical way to prevent symptoms. However, avoidance is not always possible. Knowledge of their temperature threshold can help patients to recognize and avoid critical cold exposure in their daily lives [<a href="#rid53">53</a>]. (See <a class="local">'Threshold testing'</a> above.)</p><p class="headingAnchor" id="H3768893"><span class="h2">Treatment of acute signs and symptoms</span></p><p class="headingAnchor" id="H1486254"><span class="h3">Epinephrine for systemic symptoms</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> is an effective treatment for anaphylaxis caused by other triggers, and it appears to be effective in this setting as well, based on clinical experience and case reports [<a href="#rid64">64,65</a>]. We recommend that patients with cold urticaria who have a history of anaphylaxis, systemic symptoms, frequent and unavoidable cold exposure, and/or a high temperature threshold be prescribed and carry an epinephrine autoinjector and be taught how and when to use this device [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/388.html" rel="external">"Prescribing epinephrine for anaphylaxis self-treatment"</a> and  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a> and  <a class="medical medical_review" href="/d/html/391.html" rel="external">"Anaphylaxis: Confirming the diagnosis and determining the cause(s)"</a> and  <a class="medical medical_patient" href="/d/html/365.html" rel="external">"Patient education: Using an epinephrine autoinjector (Beyond the Basics)"</a>.)</p><p class="headingAnchor" id="H3768986"><span class="h3">Treatment of milder symptoms</span><span class="headingEndMark"> — </span>We also recommend that patients carry a few doses of H1 antihistamine for use in treating systemic symptoms that do not require therapy with <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> (eg, extensive urticaria and/or angioedema not involving the airway). Patients with significant angioedema may benefit from a short course of oral glucocorticoids.</p><p class="headingAnchor" id="H1738276102"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Disease activity may be monitored with either the cold urticaria activity score (ColdUAS) or the urticaria control test (UCT):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ColdUAS </strong>– The ColdUAS is a self-administered questionnaire for prospective daily assessment of disease activity [<a href="#rid67">67</a>]. It consists of four items: the frequency and severity of wheals and/or angioedema, the frequency and severity of itch and burn, exposure to eliciting triggers, and avoidance of these triggers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>UCT</strong> – The UCT is used to monitor disease control and response to treatment, with a recall period of four weeks [<a href="#rid68">68,69</a>]. It is a four-question, retrospective, patient-reported outcome measure with a minimum value of 0 points (no control) and a maximum value of 16 points (complete control). A UCT score of ≤11 points indicates poorly controlled urticaria, a UCT score of 12 to 15 points reflects well-controlled disease, and a UCT score of 16 shows complete control.</p><p></p><p class="headingAnchor" id="H3768840"><span class="h2">Preventative therapies</span><span class="headingEndMark"> — </span>Aside from avoidance of cold exposure, H1 antihistamines are the primary prophylactic therapy for cold urticaria. Other therapies have been reported to be helpful in small series.</p><p class="headingAnchor" id="H1487514"><span class="h3">H1 antihistamines</span><span class="headingEndMark"> — </span>H1 antihistamines have been shown in small, randomized trials to reduce the frequency and severity of urticaria/angioedema episodes, as with other forms of chronic urticaria [<a href="#rid70">70-75</a>]. (See  <a class="medical medical_review" href="/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education", section on 'H1 antihistamines'</a>.)</p><p class="headingAnchor" id="H1817261335"><span class="h4">Choice of agent</span><span class="headingEndMark"> — </span>Nonsedating second-generation H1 antihistamines are preferred for chronic treatment, although some of these medications may be sedating at higher doses. Several H1 antihistamines have demonstrated efficacy in patients with cold urticaria (eg, <a class="drug drug_general" data-topicid="9572" href="/d/drug information/9572.html" rel="external">loratadine</a>, <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a>, <a class="drug drug_general" data-topicid="8472" href="/d/drug information/8472.html" rel="external">desloratadine</a>, ebastine, <a class="drug drug_general" data-topicid="112988" href="/d/drug information/112988.html" rel="external">rupatadine</a>, and <a class="drug drug_general" data-topicid="112241" href="/d/drug information/112241.html" rel="external">bilastine</a>; the last three are not available in the United States), whereas others have not been studied (eg, <a class="drug drug_general" data-topicid="9443" href="/d/drug information/9443.html" rel="external">levocetirizine</a> and <a class="drug drug_general" data-topicid="8445" href="/d/drug information/8445.html" rel="external">fexofenadine</a>) [<a href="#rid70">70-73,75,76</a>]. The effects of antihistaminic treatment on histamine-induced wheals do not predict the clinical benefit of treatment in patients [<a href="#rid77">77</a>].</p><p><a class="drug drug_general" data-topicid="9311" href="/d/drug information/9311.html" rel="external">Cyproheptadine</a> was commonly used in the past for treatment of cold urticaria. However, this drug is not known to be superior to other antihistamines for the treatment of cold urticaria, and it has the well-known adverse effects of the older first-generation antihistamines (eg, sedation, anticholinergic effects) [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H4449650"><span class="h4">Dose</span><span class="headingEndMark"> — </span>A higher-than-usual dose of antihistamine (eg, up to four times the daily recommended dose) is required for sufficient protection from urticarial symptoms in many patients with cold urticaria [<a href="#rid71">71,72,74,75,79</a>]. We start with the standard daily dose of a nonsedating second-generation antihistamine and increase it up to four times that dose if the patient continues to experience symptoms. Systematic reviews confirm that greater doses of nonsedating antihistamines are more effective than standard doses in controlling symptoms and that increasing the dose is not significantly associated with higher adverse event rates [<a href="#rid80">80</a>].</p><p>Studies evaluating the effects of various doses of antihistamines in patients with cold urticaria include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Desloratadine</strong><strong> </strong>– The need for higher-than-standard doses was demonstrated in a randomized, three-way crossover trial of 30 patients with cold urticaria who were treated with 5 or 20 mg of <a class="drug drug_general" data-topicid="8472" href="/d/drug information/8472.html" rel="external">desloratadine</a> or placebo daily (each for 7 days separated by 14-day washout periods) [<a href="#rid71">71</a>]. Response to therapy was assessed by cold stimulation test (CST) using TempTest 4.0. Both antihistamine doses decreased wheal size 15 and 90 minutes after cold provocation testing, improved the critical temperature threshold, and increased the critical stimulation time compared with placebo. The 20 mg dose was significantly more effective than the 5 mg dose for each of the endpoints.</p><p></p><p class="bulletIndent1">Even with higher antihistamine doses, responses are variable and difficult to predict. This was shown in a subsequent randomized study of 30 patients, in which one-half received 5 mg <a class="drug drug_general" data-topicid="8472" href="/d/drug information/8472.html" rel="external">desloratadine</a> daily for six weeks, while the other one-half had the dose of desloratadine increased every two weeks to a maximum of 20 mg daily if symptoms were not controlled [<a href="#rid74">74</a>]. The severity of disease (ie, the higher the eliciting temperature, the more severe the disease) was assessed at baseline and monitored throughout by CST using the TempTest 4.0 device. No patient became symptom free on 5 mg desloratadine, while two became symptom free on 10 mg and a further three on 20 mg desloratadine daily. Approximately 20 percent of patients did not experience any significant improvement, and there was no correlation between initial severity and response to therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bilastine</strong><strong> </strong>– In a randomized trial of 20 patients with cold urticaria, subjects were treated with different doses of <a class="drug drug_general" data-topicid="112241" href="/d/drug information/112241.html" rel="external">bilastine</a> or placebo in a 12-week crossover study. They received placebo, 20, 40, or 80 mg of bilastine daily, each for 7 days with 14-day washout periods. Bilastine 20 mg (the standard dose) was highly effective in reducing critical temperature thresholds. Sequentially increasing the dose to 80 mg significantly increased its effectiveness. At this higher dose, 19 of 20 (95 percent) patients responded to treatment, and 12 of 20 (60 percent) became symptom free. Only one patient was refractory to treatment. Microdialysis levels of histamine, interleukin (IL) 6, and IL-8 assessed one to three hours after cold challenge were significantly decreased following up-dosing with 80 mg bilastine. Bilastine treatment was well tolerated, without evidence of increased sedation with dose escalation [<a href="#rid75">75</a>]. Bilastine is not available in the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rupatadine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="112988" href="/d/drug information/112988.html" rel="external">Rupatadine</a>, a nonsedating H1 antihistamine with additional antagonist effects on platelet-activating factor (PAF), was shown in randomized trials and observational trials to reduce symptoms of cold urticaria at doses of 20 or 40 mg daily [<a href="#rid72">72,81-83</a>]. Rupatadine is not available in the United States.</p><p></p><p class="headingAnchor" id="H2489516523"><span class="h3">Antihistamine-refractory symptoms</span><span class="headingEndMark"> — </span>In patients with continued symptoms interfering with work or valued activities despite high-dose H1 antihistamines, treatment options include anti-IgE therapy (<a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a>) or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Omalizumab</strong><strong> </strong>– <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">Omalizumab</a> has been reported to control symptoms in multiple case reports [<a href="#rid13">13,84-88</a>] and a placebo-controlled trial [<a href="#rid14">14</a>]. We initiate therapy at 300 mg every four weeks. Patients who respond to omalizumab typically do so within a couple of weeks, at which point antihistamines can be tapered down and discontinued. For patients who do not respond to 300 mg every four weeks, we increase the dose up to 600 mg. When a patient has responded fully, we typically extend the dosing interval (eg, to five weeks or six weeks) to see if the patient begins to react to cold again. If patients appear to be in remission, omalizumab can be discontinued after 12 months. Some patients only need omalizumab in the coldest months of the year. (See  <a class="medical medical_review" href="/d/html/8111.html" rel="external">"Chronic spontaneous urticaria: Treatment of refractory symptoms", section on 'Omalizumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a>, at an initial dose of 3 mg/kg daily with subsequent dose reduction after the first month of treatment, was successful in controlling symptoms in a patient refractory to high-dose antihistamines and glucocorticoids [<a href="#rid89">89</a>]. The use of cyclosporine in chronic urticaria, including dosing and monitoring, is reviewed separately. (See  <a class="medical medical_review" href="/d/html/8111.html" rel="external">"Chronic spontaneous urticaria: Treatment of refractory symptoms", section on 'Cyclosporine'</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Other pharmacotherapy</span><span class="headingEndMark"> — </span>Several other therapies have been administered to patients with cold urticaria, as noted in case reports:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics </strong>– Antibiotic therapy was reported to be effective for some patients with cold urticaria in three observational studies [<a href="#rid6">6,90,91</a>]. In one of these series, 46 percent (13 of 28) of patients treated with high-dose oral penicillin or <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> for two to four weeks went into remission, and an additional 29 percent noted attenuated symptoms [<a href="#rid6">6</a>]. The explanation for the apparent benefit of antibiotics is unclear since patients responded regardless of whether an underlying infection could be detected, and the antiinflammatory properties of some antibiotics would explain a temporary benefit but not remission of disease.</p><p></p><p class="bulletIndent1">In the author's clinic, patients are treated initially (ie, even before prescribing daily antihistamines) with a three-week course of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (adult dose 100 mg twice daily), followed by three weeks of observation since the response to treatment usually occurs in the weeks after the antibiotics are finished. We initially chose doxycycline because it is safe and inexpensive. Randomized, controlled trials are needed to assess the efficacy of this treatment, and, until better data are available, we are reluctant to promote the wider use of this approach [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>H2 antihistamines </strong>– H2 antihistamines (eg, <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> 20 mg twice daily) added to H1 antihistamines are helpful in some patients [<a href="#rid92">92</a>]. However, other patients experience no apparent benefit, and more conclusive studies are lacking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antileukotriene agents </strong>– The addition of the leukotriene antagonists <a class="drug drug_general" data-topicid="9539" href="/d/drug information/9539.html" rel="external">montelukast</a> or <a class="drug drug_general" data-topicid="10052" href="/d/drug information/10052.html" rel="external">zafirlukast</a> appeared to be beneficial in some patients [<a href="#rid93">93,94</a>], although not in others [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other biologics </strong>– <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">Etanercept</a> and <a class="drug drug_general" data-topicid="115768" href="/d/drug information/115768.html" rel="external">benralizumab</a> have been reported to be of benefit in a single case report each [<a href="#rid96">96,97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>capsaicin</strong><strong> </strong>– Treatment with topical <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">capsaicin</a>, derived from chili peppers, prevented cold urticaria symptoms for four to seven days in a small case series [<a href="#rid98">98</a>]. However, it causes local irritation at the site of application. Capsaicin treatment results in the depletion of neuropeptides from sensory nerve fibers that may contribute to the induction of cold urticaria skin reactions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral glucocorticoids </strong>– Response to systemic glucocorticoids is variable and therefore not recommended for routine treatment of cold urticaria [<a href="#rid89">89,99</a>]. Most patients do not report improvement, and this may be related to the absence of a late-phase cellular infiltrate. Those who do respond usually report only temporary improvement [<a href="#rid100">100</a>].</p><p></p><p class="headingAnchor" id="H2682769933"><span class="h2">Adjustment and discontinuation of therapy</span><span class="headingEndMark"> — </span>For patients who have been entirely protected from cold-induced symptoms for at least six weeks on a higher-than-standard dose, the dose is then decreased over several months to the lowest level that provides complete protection. Patients are continued on a prophylactic antihistamine until they go into remission. The author typically discontinues the medication after six months to determine if remission has been achieved. Patients who participate in aquatic activities in the summer usually require year-round treatment, whereas others may need protection only during the winter months. The author routinely performs threshold tests with TempTest 4.0 to assess the efficacy of antihistamine therapy.</p><p class="headingAnchor" id="H14"><span class="h2">Cold desensitization</span><span class="headingEndMark"> — </span>Desensitization to cold (cold "tolerance" induction or hardening) by repeatedly exposing the patient to baths/showers in cold water is another option for treatment, although it carries the risk of inducing systemic symptoms and must be performed under a clinician's supervision. In addition, it is not practical for most patients, because daily cold showers/baths are required to maintain the desensitized state. Still, several case series suggest that cold desensitization can be used as therapy [<a href="#rid101">101-103</a>]. Patients are desensitized to the cold by repeatedly exposing increasingly larger skin areas to incrementally colder water, starting with above-threshold temperatures. This therapy decreases the critical temperature threshold and protects the patient from future cold-induced symptoms.</p><p>Cold-tolerance induction needs to be initiated with great caution and under a clinician's supervision because of the risk of severe systemic reactions. While the term "tolerance" is used, "desensitization" is more appropriate since discontinuation for as little as a few days results in a complete loss of protection. Patients need to be informed that daily cold showers/baths are required to maintain the desensitized state. For this reason, most patients do not continue this therapy for more than a few weeks to months.</p><p class="headingAnchor" id="H548347974"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/108976.html" rel="external">"Society guideline links: Urticaria and angioedema (excluding hereditary angioedema)"</a>.)</p><p class="headingAnchor" id="H362177252"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/87116.html" rel="external">"Patient education: Inducible hives (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and pathogenesis </strong>– Cold urticaria is a subtype of physical urticaria characterized by itchy wheals and/or angioedema due to skin mast cell activation and the release of proinflammatory mediators after cold exposure  (<a class="graphic graphic_picture graphicRef50151" href="/d/graphic/50151.html" rel="external">picture 1</a>). Most cases of cold urticaria are idiopathic, although, in some patients, cold urticaria is associated with infections, a preceding insect sting, or a hematologic disorder. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signs and symptoms </strong>– Cold urticaria presents with urticaria and/or angioedema affecting cold-exposed skin areas, which develops within minutes of cold exposure. Extensive cold contact may result in systemic reactions. Occurrence of severe anaphylactic reactions or suffocation due to oropharyngeal edema is possible. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis should be suspected in a patient who develops urticaria and/or angioedema after the skin is exposed to cold air, liquids, or objects  (<a class="graphic graphic_picture graphicRef50151" href="/d/graphic/50151.html" rel="external">picture 1</a>). Symptoms usually develop some minutes after cold exposure and are usually limited to cold-exposed skin areas. Laboratory testing is not needed in routine cases. The diagnosis is confirmed by the presence of a positive cold stimulation test (CST)  (<a class="graphic graphic_picture graphicRef95909" href="/d/graphic/95909.html" rel="external">picture 2</a>). If the CST does not reproduce urticaria, the patient may have a form of atypical cold urticaria or a different cold-related disorder. (See <a class="local">'Evaluation'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– Cold-induced systemic inflammation (eg, fever, arthralgias) or purpuric lesions in response to cold suggest other disorders. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of high-risk situations </strong>– Avoidance of cold exposure is the best prophylaxis, although complete avoidance is difficult for most patients. Patients should be educated about high-risk activities and situations, such as swimming, surgery, and ingestion of cold foods and beverages. (See <a class="local">'Education about high-risk activities and cold avoidance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epinephrine</strong><strong> for systemic reactions </strong>– We prescribe <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors for those patients with a history of anaphylaxis, systemic symptoms, frequent or unavoidable cold exposure, and/or a high temperature threshold. We advise such patients to carry epinephrine at all times and periodically review how and when to administer it. (See <a class="local">'Epinephrine for systemic symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventative H1 antihistamines </strong>– We recommend nonsedating second-generation H1 antihistamines for patients with cold urticaria who are unable to sufficiently avoid cold exposure and have frequent symptoms (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We typically begin with the standard dose and increase up to four times this dose, as needed, to control symptoms. Most patients respond, although some have residual symptoms. (See <a class="local">'H1 antihistamines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Omalizumab</strong><strong> for refractory symptoms </strong>– For patients with symptoms refractory to higher doses of H1 antihistamines, we suggest <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) in preference to other therapies. Successful treatment with several other therapies has been described in case reports and may be used if omalizumab is not available. (See <a class="local">'Antihistamine-refractory symptoms'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy 2016; 71:780.</a></li><li><a class="nounderline abstract_t">Abajian M, Młynek A, Maurer M. Physical urticaria. Curr Allergy Asthma Rep 2012; 12:281.</a></li><li><a class="nounderline abstract_t">Abajian M, Schoepke N, Altrichter S, et al. Physical urticarias and cholinergic urticaria. Immunol Allergy Clin North Am 2014; 34:73.</a></li><li><a class="nounderline abstract_t">Katsarou-Katsari A, Makris M, Lagogianni E, et al. Clinical features and natural history of acquired cold urticaria in a tertiary referral hospital: a 10-year prospective study. J Eur Acad Dermatol Venereol 2008; 22:1405.</a></li><li><a class="nounderline abstract_t">Neittaanmäki H. Cold urticaria. Clinical findings in 220 patients. J Am Acad Dermatol 1985; 13:636.</a></li><li><a class="nounderline abstract_t">Möller A, Henning M, Zuberbier T, Czarnetzki-Henz BM. [Epidemiology and clinical aspects of cold urticaria]. Hautarzt 1996; 47:510.</a></li><li><a class="nounderline abstract_t">Wanderer AA, Grandel KE, Wasserman SI, Farr RS. Clinical characteristics of cold-induced systemic reactions in acquired cold urticaria syndromes: recommendations for prevention of this complication and a proposal for a diagnostic classification of cold urticaria. J Allergy Clin Immunol 1986; 78:417.</a></li><li><a class="nounderline abstract_t">Yee CSK, El Khoury K, Albuhairi S, et al. Acquired Cold-Induced Urticaria in Pediatric Patients: A 22-Year Experience in a Tertiary Care Center (1996-2017). J Allergy Clin Immunol Pract 2019; 7:1024.</a></li><li><a class="nounderline abstract_t">Alangari AA, Twarog FJ, Shih MC, Schneider LC. Clinical features and anaphylaxis in children with cold urticaria. Pediatrics 2004; 113:e313.</a></li><li class="breakAll">Moller A, Henz BM. Cold urticaria. In: Urticaria: Clinical, diagnostic, and therapeutic aspects, Henz BM, Zuberbier T, Grabbe J, Monroe E (Eds), Springer, Berlin 1998.</li><li><a class="nounderline abstract_t">Moreno JN, Harfi HA. Cold urticaria in Saudi Arabia. Ann Allergy 1989; 63:331.</a></li><li><a class="nounderline abstract_t">Siebenhaar F, Weller K, Mlynek A, et al. Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol 2007; 32:241.</a></li><li><a class="nounderline abstract_t">Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J Allergy Clin Immunol 2018; 141:638.</a></li><li><a class="nounderline abstract_t">Metz M, Schütz A, Weller K, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol 2017; 140:864.</a></li><li><a class="nounderline abstract_t">Kaplan AP, Garofalo J, Sigler R, Hauber T. Idiopathic cold urticaria: in vitro demonstration of histamine release upon challenge of skin biopsies. N Engl J Med 1981; 305:1074.</a></li><li><a class="nounderline abstract_t">Kaplan AP, Gray L, Shaff RE, et al. In vivo studies of mediator release in cold urticaria and cholinergic urticaria. J Allergy Clin Immunol 1975; 55:394.</a></li><li><a class="nounderline abstract_t">Wanderer AA, Hoffman HM. The spectrum of acquired and familial cold-induced urticaria/urticaria-like syndromes. Immunol Allergy Clin North Am 2004; 24:259.</a></li><li><a class="nounderline abstract_t">Kulthanan K, Church MK, Grekowitz EM, et al. Evidence for histamine release in chronic inducible urticaria - A systematic review. Front Immunol 2022; 13:901851.</a></li><li><a class="nounderline abstract_t">Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114:465.</a></li><li><a class="nounderline abstract_t">Gruber BL, Baeza ML, Marchese MJ, et al. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988; 90:213.</a></li><li><a class="nounderline abstract_t">Nilsson T, Bäck O. On the role of the C1-esterase inhibitor in cold urticaria. Acta Derm Venereol 1984; 64:197.</a></li><li><a class="nounderline abstract_t">Wasserman SI, Ginsberg MH. Release of platelet factor 4 into the blood after cold challenge of patients with cold urticaria. J Allergy Clin Immunol 1984; 74:275.</a></li><li><a class="nounderline abstract_t">Grandel KE, Farr RS, Wanderer AA, et al. Association of platelet-activating factor with primary acquired cold urticaria. N Engl J Med 1985; 313:405.</a></li><li><a class="nounderline abstract_t">Stafford CT, Jamieson DM. Cold urticaria associated with C4 deficiency and elevated IgM. Ann Allergy 1986; 56:313.</a></li><li><a class="nounderline abstract_t">Petit A, Schnitzler L, Lassoued K, et al. Anti-lamin-B autoantibodies in a patient with cold urticaria. Dermatology 1992; 185:143.</a></li><li><a class="nounderline abstract_t">Lemanske RF Jr, Bush RK. Cold urticaria in infectious mononucleosis. JAMA 1982; 247:1604.</a></li><li><a class="nounderline abstract_t">Doeglas HM, Rijnten WJ, Schröder FP, Schirm J. Cold urticaria and virus infections: a clinical and serological study in 39 patients. Br J Dermatol 1986; 114:311.</a></li><li><a class="nounderline abstract_t">Lin RY, Schwartz RA. Cold urticaria and HIV infection. Br J Dermatol 1993; 129:465.</a></li><li><a class="nounderline abstract_t">Kränke B, Mayr-Kanhäuser S, Aberer W. Helicobacter pylori in acquired cold urticaria. Contact Dermatitis 2001; 44:57.</a></li><li><a class="nounderline abstract_t">Miralles López JC, López Andreu FR, Sánchez-Gascón F, et al. Cold urticaria associated with acute serologic toxoplasmosis. Allergol Immunopathol (Madr) 2005; 33:172.</a></li><li><a class="nounderline abstract_t">Kalogeromitros D, Gregoriou S, Papaioannou D, et al. Acquired primary cold contact urticaria after Hymenoptera sting. Clin Exp Dermatol 2004; 29:93.</a></li><li><a class="nounderline abstract_t">Hogendijk S, Hauser C. Wasp sting-associated cold urticaria. Allergy 1997; 52:1145.</a></li><li><a class="nounderline abstract_t">Kutlu A, Aydin E, Goker K, et al. Cold-induced urticaria with systemic reactions after hymenoptera sting lasting for 10 years. Allergol Immunopathol (Madr) 2013; 41:283.</a></li><li><a class="nounderline abstract_t">Wong CG, Borici-Mazi R. Delayed-onset cold anaphylaxis after hymenoptera sting. Ann Allergy Asthma Immunol 2012; 109:77.</a></li><li><a class="nounderline abstract_t">Gandolfo-Cano M, González-Mancebo E, González-de Olano D, et al. Cold urticaria induced by alprazolam. J Investig Allergol Clin Immunol 2012; 22:222.</a></li><li><a class="nounderline abstract_t">Doeglas HM. Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias. Br J Dermatol 1975; 93:135.</a></li><li><a class="nounderline abstract_t">Mathelier-Fusade P, Aïssaoui M, Bakhos D, et al. Clinical predictive factors of severity in cold urticaria. Arch Dermatol 1998; 134:106.</a></li><li><a class="nounderline abstract_t">Prosty C, Gabrielli S, Mule P, et al. Cold urticaria in a pediatric cohort: Clinical characteristics, management, and natural history. Pediatr Allergy Immunol 2022; 33:e13751.</a></li><li><a class="nounderline abstract_t">Bizjak M, Košnik M, Dinevski D, et al. Risk factors for systemic reactions in typical cold urticaria: Results from the COLD-CE study. Allergy 2022; 77:2185.</a></li><li><a class="nounderline abstract_t">Maltseva N, Borzova E, Fomina D, et al. Cold urticaria - What we know and what we do not know. Allergy 2021; 76:1077.</a></li><li><a class="nounderline abstract_t">Deza G, Brasileiro A, Bertolín-Colilla M, et al. Acquired cold urticaria: Clinical features, particular phenotypes, and disease course in a tertiary care center cohort. J Am Acad Dermatol 2016; 75:918.</a></li><li><a class="nounderline abstract_t">Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006; 61:316.</a></li><li><a class="nounderline abstract_t">Bäck O, Larsen A. Delayed cold urticaria. Acta Derm Venereol 1978; 58:369.</a></li><li><a class="nounderline abstract_t">Matthews CN, Warin RP. Delayed cold urticaria. Br J Dermatol 1977; 97 Suppl 15:32.</a></li><li><a class="nounderline abstract_t">Gandhi C, Healy C, Wanderer AA, Hoffman HM. Familial atypical cold urticaria: description of a new hereditary disease. J Allergy Clin Immunol 2009; 124:1245.</a></li><li><a class="nounderline abstract_t">Kaplan AP. Unusual cold-induced disorders: cold-dependent dermatographism and systemic cold urticaria. J Allergy Clin Immunol 1984; 73:453.</a></li><li><a class="nounderline abstract_t">Matthews CN, Warin RP. Cold urticaria and cold precipitated dermographism. Br J Dermatol 1970; 82:91.</a></li><li><a class="nounderline abstract_t">Kaplan AP, Garofalo J. Identification of a new physically induced urticaria: cold-induced cholinergic urticaria. J Allergy Clin Immunol 1981; 68:438.</a></li><li><a class="nounderline abstract_t">Wanderer AA. Cold urticaria syndromes: historical background, diagnostic classification, clinical and laboratory characteristics, pathogenesis, and management. J Allergy Clin Immunol 1990; 85:965.</a></li><li><a class="nounderline abstract_t">Sciallis GF 2nd, Krych EH. Localized cold urticaria to the face in a pediatric patient: a case report and literature review. Pediatr Dermatol 2010; 27:266.</a></li><li><a class="nounderline abstract_t">Kurtz AS, Kaplan AP. Regional expression of cold urticaria. J Allergy Clin Immunol 1990; 86:272.</a></li><li><a class="nounderline abstract_t">Kulthanan K, Tuchinda P, Chularojanamontri L, Maurer M. Food-dependent cold urticaria: A new variant of physical urticaria. J Allergy Clin Immunol Pract 2018; 6:1400.</a></li><li><a class="nounderline abstract_t">Siebenhaar F, Staubach P, Metz M, et al. Peltier effect-based temperature challenge: an improved method for diagnosing cold urticaria. J Allergy Clin Immunol 2004; 114:1224.</a></li><li><a class="nounderline abstract_t">Magerl M, Borzova E, Giménez-Arnau A, et al. The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy 2009; 64:1715.</a></li><li><a class="nounderline abstract_t">Wanderer AA, St Pierre JP, Ellis EF. Primary acquired cold urticaria. Double-blind comparative study of treatment with cyproheptadine, chlorpheniramine, and placebo. Arch Dermatol 1977; 113:1375.</a></li><li><a class="nounderline abstract_t">Mlynek A, Bär M, Bauer A, Meurer M. Juvenile pemphigus foliaceus associated with severe nonscarring alopecia. Br J Dermatol 2009; 161:472.</a></li><li><a class="nounderline abstract_t">Młynek A, Magerl M, Siebenhaar F, et al. Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. Br J Dermatol 2010; 162:198.</a></li><li><a class="nounderline abstract_t">Pérez-Bustillo A, Sánchez-Sambucety P, García-Ruiz de Morales JM, Rodríguez-Prieto MÁ. Cold-induced urticarial vasculitis. Int J Dermatol 2012; 51:881.</a></li><li><a class="nounderline abstract_t">Ombrello MJ, Remmers EF, Sun G, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 2012; 366:330.</a></li><li><a class="nounderline abstract_t">Scheffel J, Mahnke NA, Hofman ZLM, et al. Cold-induced urticarial autoinflammatory syndrome related to factor XII activation. Nat Commun 2020; 11:179.</a></li><li><a class="nounderline abstract_t">Hofman ZLM, Clark CC, Sanrattana W, et al. A mutation in the kringle domain of human factor XII that causes autoinflammation, disturbs zymogen quiescence, and accelerates activation. J Biol Chem 2020; 295:363.</a></li><li><a class="nounderline abstract_t">Booth K, Parissis H. Management of cold-induced urticaria during cardiac surgery. J Card Surg 2011; 26:158.</a></li><li><a class="nounderline abstract_t">De la Borbolla JM, Tapies S, Mbongo C, et al. Cold urticaria: its importance in the operating room. J Investig Allergol Clin Immunol 2010; 20:446.</a></li><li><a class="nounderline abstract_t">La Shell MS, Tankersley MS, Kobayashi M. Cold urticaria: a case report and review of the literature. Cutis 2005; 76:257.</a></li><li><a class="nounderline abstract_t">Bird JA, Burks W. Peanut allergy saves a patient with cold-induced hypotension and urticaria. J Pediatr 2010; 156:687.</a></li><li><a class="nounderline abstract_t">Bizjak M, Košnik M, Dinevski D, et al. Adrenaline autoinjector is underprescribed in typical cold urticaria patients. Allergy 2022; 77:2224.</a></li><li><a class="nounderline abstract_t">Ahsan DM, Altrichter S, Gutsche A, et al. Development of the Cold Urticaria Activity Score. Allergy 2022; 77:2509.</a></li><li><a class="nounderline abstract_t">Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014; 133:1365.</a></li><li><a class="nounderline abstract_t">Ohanyan T, Schoepke N, Bolukbasi B, et al. Responsiveness and minimal important difference of the urticaria control test. J Allergy Clin Immunol 2017; 140:1710.</a></li><li><a class="nounderline abstract_t">Magerl M, Schmolke J, Siebenhaar F, et al. Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy 2007; 62:1465.</a></li><li><a class="nounderline abstract_t">Siebenhaar F, Degener F, Zuberbier T, et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009; 123:672.</a></li><li><a class="nounderline abstract_t">Metz M, Scholz E, Ferrán M, et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol 2010; 104:86.</a></li><li><a class="nounderline abstract_t">Villas Martínez F, Contreras FJ, López Cazaña JM, et al. A comparison of new nonsedating and classical antihistamines in the treatment of primary acquired cold urticaria (ACU). J Investig Allergol Clin Immunol 1992; 2:258.</a></li><li><a class="nounderline abstract_t">Magerl M, Pisarevskaja D, Staubach P, et al. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1) -antihistamine dose escalation. Br J Dermatol 2012; 166:1095.</a></li><li><a class="nounderline abstract_t">Krause K, Spohr A, Zuberbier T, et al. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68:921.</a></li><li><a class="nounderline abstract_t">Nettis E, Delle Donne P, Di Leo E, et al. Rupatadine for the treatment of urticaria. Expert Opin Pharmacother 2013; 14:1807.</a></li><li><a class="nounderline abstract_t">Gorczyza M, Curto-Barredo L, Krause K, et al. H1-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria. J Allergy Clin Immunol Pract 2019; 7:2043.</a></li><li><a class="nounderline abstract_t">Visitsunthorn N, Tuchinda M, Vichyanond P. Cold urticaria in Thai children: comparison between cyproheptadine and ketotifen in the treatment. Asian Pac J Allergy Immunol 1995; 13:29.</a></li><li><a class="nounderline abstract_t">Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006; 61:321.</a></li><li><a class="nounderline abstract_t">Kulthanan K, Hunnangkul S, Tuchinda P, et al. Treatments of cold urticaria: A systematic review. J Allergy Clin Immunol 2019; 143:1311.</a></li><li><a class="nounderline abstract_t">Abajian M, Curto-Barredo L, Krause K, et al. Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria. Acta Derm Venereol 2016; 96:56.</a></li><li><a class="nounderline abstract_t">Martinez-Escala ME, Curto-Barredo L, Carnero L, et al. Temperature thresholds in assessment of the clinical course of acquired cold contact urticaria: a prospective observational one-year study. Acta Derm Venereol 2015; 95:278.</a></li><li><a class="nounderline abstract_t">Di Leo E, Nettis E, Cassano N, et al. Treatment of acquired cold urticaria with rupatadine. Allergy 2009; 64:1387.</a></li><li><a class="nounderline abstract_t">Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006; 117:1415.</a></li><li><a class="nounderline abstract_t">Metz M, Altrichter S, Ardelean E, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011; 154:177.</a></li><li><a class="nounderline abstract_t">Brodská P, Schmid-Grendelmeier P. Treatment of severe cold contact urticaria with omalizumab: case reports. Case Rep Dermatol 2012; 4:275.</a></li><li><a class="nounderline abstract_t">Le Moing A, Bécourt C, Pape E, et al. Effective treatment of idiopathic chronic cold urticaria with omalizumab: report of 3 cases. J Am Acad Dermatol 2013; 69:e99.</a></li><li><a class="nounderline abstract_t">Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci 2014; 73:57.</a></li><li><a class="nounderline abstract_t">Marsland AM, Beck MH. Cold urticaria responding to systemic ciclosporin. Br J Dermatol 2003; 149:214.</a></li><li><a class="nounderline abstract_t">Raap U, Liekenbröcker T, Wieczorek D, et al. [New therapeutic strategies for the different subtypes of urticaria]. Hautarzt 2004; 55:361.</a></li><li><a class="nounderline abstract_t">Gorczyza M, Schoepke N, Krause K, et al. Patients with chronic cold urticaria may benefit from doxycycline therapy. Br J Dermatol 2017; 176:259.</a></li><li><a class="nounderline abstract_t">Duc J, Pécoud A. Successful treatment of idiopathic cold urticaria with the association of H1 and H2 antagonists: a case report. Ann Allergy 1986; 56:355.</a></li><li><a class="nounderline abstract_t">Bonadonna P, Lombardi C, Senna G, et al. Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. J Am Acad Dermatol 2003; 49:714.</a></li><li><a class="nounderline abstract_t">Hani N, Hartmann K, Casper C, et al. Improvement of cold urticaria by treatment with the leukotriene receptor antagonist montelukast. Acta Derm Venereol 2000; 80:229.</a></li><li><a class="nounderline abstract_t">Nuutinen P, Harvima IT, Ackermann L. Histamine, but not leukotriene C4, is an essential mediator in cold urticaria wheals. Acta Derm Venereol 2007; 87:9.</a></li><li><a class="nounderline abstract_t">Gualdi G, Monari P, Rossi MT, et al. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis. Br J Dermatol 2012; 166:1373.</a></li><li><a class="nounderline abstract_t">Maurer M, Altrichter S, Metz M, et al. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. J Eur Acad Dermatol Venereol 2018; 32:e112.</a></li><li><a class="nounderline abstract_t">Tóth-Kása I, Jancsó G, Obál F Jr, et al. Involvement of sensory nerve endings in cold and heat urticaria. J Invest Dermatol 1983; 80:34.</a></li><li><a class="nounderline abstract_t">Black AK, Eady RA, Greaves MW, et al. Treatment of acquired cold urticaria by prednisone: dissociation of histamine release and clinical improvement [proceedings]. Br J Clin Pharmacol 1980; 9:116P.</a></li><li><a class="nounderline abstract_t">Claudy A. Cold urticaria. J Investig Dermatol Symp Proc 2001; 6:141.</a></li><li><a class="nounderline abstract_t">Black AK, Sibbald RG, Greaves MW. Cold urticaria treated by induction of tolerance. Lancet 1979; 2:964.</a></li><li><a class="nounderline abstract_t">von Mackensen YA, Sticherling M. Cold urticaria: tolerance induction with cold baths. Br J Dermatol 2007; 157:835.</a></li><li><a class="nounderline abstract_t">Kring Tannert L, Stahl Skov P, Bjerremann Jensen L, et al. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction. Dermatology 2012; 224:101.</a></li></ol></div><div id="topicVersionRevision">Topic 8102 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26991006" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22653630" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Physical urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24262690" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Physical urticarias and cholinergic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19120806" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical features and natural history of acquired cold urticaria in a tertiary referral hospital: a 10-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4078052" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cold urticaria. Clinical findings in 220 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8926165" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : [Epidemiology and clinical aspects of cold urticaria].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3760401" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical characteristics of cold-induced systemic reactions in acquired cold urticaria syndromes: recommendations for prevention of this complication and a proposal for a diagnostic classification of cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30385406" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acquired Cold-Induced Urticaria in Pediatric Patients: A 22-Year Experience in a Tertiary Care Center (1996-2017).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15060259" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical features and anaphylaxis in children with cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15060259" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical features and anaphylaxis in children with cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2802271" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cold urticaria in Saudi Arabia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17355280" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acquired cold urticaria: clinical picture and update on diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28751232" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28389393" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6168912" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Idiopathic cold urticaria: in vitro demonstration of histamine release upon challenge of skin biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/48522" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : In vivo studies of mediator release in cold urticaria and cholinergic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15120151" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The spectrum of acquired and familial cold-induced urticaria/urticaria-like syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35967442" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Evidence for histamine release in chronic inducible urticaria - A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356542" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chronic urticaria: pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2448392" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6204479" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : On the role of the C1-esterase inhibitor in cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6470362" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Release of platelet factor 4 into the blood after cold challenge of patients with cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2410790" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association of platelet-activating factor with primary acquired cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3963523" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cold urticaria associated with C4 deficiency and elevated IgM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1421628" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Anti-lamin-B autoantibodies in a patient with cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6278167" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cold urticaria in infectious mononucleosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3954951" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cold urticaria and virus infections: a clinical and serological study in 39 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8105869" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cold urticaria and HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11156032" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Helicobacter pylori in acquired cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15946632" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cold urticaria associated with acute serologic toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14723735" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acquired primary cold contact urticaria after Hymenoptera sting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9404573" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Wasp sting-associated cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23178143" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cold-induced urticaria with systemic reactions after hymenoptera sting lasting for 10 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22727165" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Delayed-onset cold anaphylaxis after hymenoptera sting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22697016" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cold urticaria induced by alprazolam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1100092" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9449923" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical predictive factors of severity in cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35338743" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cold urticaria in a pediatric cohort: Clinical characteristics, management, and natural history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34862605" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Risk factors for systemic reactions in typical cold urticaria: Results from the COLD-CE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33249577" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cold urticaria - What we know and what we do not know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27485164" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Acquired cold urticaria: Clinical features, particular phenotypes, and disease course in a tertiary care center cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16436140" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/82339" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Delayed cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/884045" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Delayed cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910034" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Familial atypical cold urticaria: description of a new hereditary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6200525" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Unusual cold-induced disorders: cold-dependent dermatographism and systemic cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5410995" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cold urticaria and cold precipitated dermographism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7310011" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Identification of a new physically induced urticaria: cold-induced cholinergic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2191995" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cold urticaria syndromes: historical background, diagnostic classification, clinical and laboratory characteristics, pathogenesis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20609144" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Localized cold urticaria to the face in a pediatric patient: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2384655" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Regional expression of cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29698807" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Food-dependent cold urticaria: A new variant of physical urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15536435" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Peltier effect-based temperature challenge: an improved method for diagnosing cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19793059" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/334082" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Primary acquired cold urticaria. Double-blind comparative study of treatment with cyproheptadine, chlorpheniramine, and placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438865" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Juvenile pemphigus foliaceus associated with severe nonscarring alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19785601" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22233132" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cold-induced urticarial vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22236196" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31924766" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cold-induced urticarial autoinflammatory syndrome related to factor XII activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31771982" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A mutation in the kringle domain of human factor XII that causes autoinflammation, disturbs zymogen quiescence, and accelerates activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208273" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Management of cold-induced urticaria during cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20945615" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cold urticaria: its importance in the operating room.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16315562" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cold urticaria: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20056234" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Peanut allergy saves a patient with cold-induced hypotension and urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35258111" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Adrenaline autoinjector is underprescribed in typical cold urticaria patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35403217" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Development of the Cold Urticaria Activity Score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24522090" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28625805" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Responsiveness and minimal important difference of the urticaria control test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17900265" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Acquired cold urticaria symptoms can be safely prevented by ebastine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19201016" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20143651" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1364168" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A comparison of new nonsedating and classical antihistamines in the treatment of primary acquired cold urticaria (ACU).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22242678" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1) -antihistamine dose escalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23742030" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Up-dosing with bilastine results in improved effectiveness in cold contact urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23806068" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Rupatadine for the treatment of urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30708143" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : H1-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7488341" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cold urticaria in Thai children: comparison between cyproheptadine and ketotifen in the treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16436141" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : EAACI/GA2LEN/EDF guideline: management of urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30776418" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Treatments of cold urticaria: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26038847" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24977664" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Temperature thresholds in assessment of the clinical course of acquired cold contact urticaria: a prospective observational one-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19392988" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Treatment of acquired cold urticaria with rupatadine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16751006" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20733327" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341807" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Treatment of severe cold contact urticaria with omalizumab: case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23866899" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effective treatment of idiopathic chronic cold urticaria with omalizumab: report of 3 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24060603" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12890231" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cold urticaria responding to systemic ciclosporin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999392" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : [New therapeutic strategies for the different subtypes of urticaria].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27343477" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Patients with chronic cold urticaria may benefit from doxycycline therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2870670" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Successful treatment of idiopathic cold urticaria with the association of H1 and H2 antagonists: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512923" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10954230" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Improvement of cold urticaria by treatment with the leukotriene receptor antagonist montelukast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17225008" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Histamine, but not leukotriene C4, is an essential mediator in cold urticaria wheals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22212112" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28924988" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6848608" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Involvement of sensory nerve endings in cold and heat urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6153528" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Treatment of acquired cold urticaria by prednisone: dissociation of histamine release and clinical improvement [proceedings].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11764302" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Cold urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/91061" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Cold urticaria treated by induction of tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17711531" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cold urticaria: tolerance induction with cold baths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22398751" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
